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The effect of clozapine on mRNA expression for genes
encoding G protein-coupled receptors and the protein
components of clathrin-mediated endocytosis
Sally I. Sharpa, Ying Huc, Jon F. Weymera, Mie Riziga, Andrew McQuillina,
Stephen P. Huntb and Hugh M.D. Gurlinga
Objectives Clathrin-mediated endocytosis (CME) is an
intracellular trafficking mechanism for packaging cargo,
including G protein-coupled receptors (GPCRs), into
clathrin-coated vesicles (CCVs). The antipsychotic
chlorpromazine inhibits CCV assembly of adaptor protein
AP2 whereas clozapine increases serotonin2A receptor
internalization. We hypothesized that clozapine alters the
expression of CME genes modulating vesicle turnover
and GPCR internalization.
Materials and methods SH-SY5Y human neuroblastoma
cells were incubated with clozapine (1–20 lmol/l) for
24–72h. GPCR and CME-related gene mRNA expression
was measured using RT-PCR. We quantified changes in the
same genes using expression data from a microarray study
of mice brains after 12 weeks of treatment with 12mg/kg/
day clozapine.
Results The expression of genes encoding adaptor and
clathrin assembly proteins, AP2A2, AP2B1, AP180, CLINT1,
HIP1, ITSN2, and PICALM, increased relative to the control
in SH-SY5Y cells incubated with 5–10 lmol/l clozapine for
24–72h. The microarray study showed significantly altered
expression of the above CME-related genes, with a marked
641-fold and 17-fold increase in AP180 and the
serotonin1A GPCR, respectively. The expression of three
serotonergic receptor and lysophosphatidic acid receptor 2
(EDG4) GPCR genes was upregulated in SH-SY5Y
cells incubated with 5lmol/l clozapine for 24h. EDG4
expression was also increased with 10–20 lmol/l
clozapine treatment at 48–72h. Clozapine significantly
decreased the expression of b-arrestin, involved in GPCR
desensitization, both in vitro and vivo.
Conclusion The changes we report in CME and GPCR
mRNAs implicate CCV-mediated internalization of GPCRs
and the serotonergic system in clozapine’s mechanism of
action, which may be useful in the design of more effective
and less toxic antipsychotic therapies. Psychiatr Genet
23:153–162 c 2013 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Schizophrenia is among the top 10 causes of disability in
developed countries worldwide (Murray, 1996) and has an
estimated heritability of 80% (McGuffin et al., 1984).
Genetic deletions and duplications are strongly associated
with schizophrenia, some of which are highly penetrant in
their effects on individual susceptibility (Need et al., 2009).
However, there is considerable heterogeneity, with many
genes associated within specific ancestral groups (Sanders
et al., 2008). Several genes that increase susceptibility to
schizophrenia are regulated by or participate in endosomal
transport mechanisms (Ryder and Faundez, 2009). Our own
schizophrenia genetic association study shows the involve-
ment of the clathrin-mediated endocytosis (CME)-related
protein enthoprotein encoded by the clathrin interactor 1
(CLINT1) gene (Pimm et al., 2005). Genetic evidence that
CLINT1 expression and structure is abnormal in schizo-
phrenia is well replicated (Liou et al., 2006; Tang et al.,
2006; Gurling et al., 2007; Escamilla et al., 2008; International
Schizophrenia Consortium, 2008; Purcell et al., 2009). It is
of particular interest that antipsychotic drugs are effective
in the majority of patients despite the many different
genetic subtypes of schizophrenia.
Antipsychotic drugs such as chlorpromazine and haloperidol
are effective in the treatment of thought disorder,
hallucinations, and delusions in patients with schizophre-
nia. The side effects of these drugs such as extrapyramidal
signs and hyperprolactinemia are mediated by dopamine
receptor antagonism, although these adverse effects do not
characterize all antipsychotics (Serretti et al., 2004). A large
number of G protein-coupled receptors (GPCRs) have an
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affinity for antipsychotic drugs. The efficacy and toler-
ability of the atypical antipsychotic clozapine in the
treatment of schizophrenia is likely to be because of strong
serotonin [5-hydroxytryptamine (5-HT)] 2A receptor
(5-HT2A) inverse agonism, 5-HT1A partial agonism, and
weak D2/D3 antagonism (Meltzer and Massey, 2011).
There is evidence that both olanzapine and clozapine, but
not haloperidol, increase clathrin-mediated internalization
of 5-HT2A (Willins et al., 1999). Unlike typical antipsycho-
tics, atypical drugs may exert a beneficial effect on
psychosis through a more complicated mechanism of action
involving chronic molecular and structural brain changes
than would be elicited by a simple drug–receptor interac-
tion (Heusler et al., 2008).
Endosomal trafficking mechanisms regulate signal transduc-
tion and presynaptic and postsynaptic neuronal cell surface
composition and function (von Zastrow and Sorkin, 2007) by
controlling the release and recycling of synaptic vesicles, as
well as the subcellular distribution of neurotransmitter
receptors and transporters (Kennedy and Ehlers, 2006).
Enthoprotin is a linker protein between the lipid bilayer of
the neuronal membrane and various adaptor proteins (AP)
and clathrin molecules, playing a crucial role in clathrin-
coated pit formation (Mills et al., 2003). The adaptors anchor
clathrin to the transmembrane, interact with the clathrin-
coated vesicle (CCV) formation machinery, and select ‘cargo’
for inclusion in CCVs (Robinson, 2004). Distinct and
potentially widespread mechanisms regulating GPCR sur-
face abundance and sorting to lysosomes are dysfunctional in
the brains of patients with schizophrenia (Marley and von
Zastrow, 2010). Thus, clozapine may exert its positive
clinical effect by regulating receptor density and trafficking.
Here, we determine the effect of clozapine on CCV and
GPCR gene expression in the mouse brain and human
neuroblastoma cells.
Materials and methods
Cell culture
Undifferentiated human neuroblastoma SH-SY5Y cells
(Catalogue no. 94030304; Health Protection Agency
Culture Collections, London, UK) were maintained in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich,
Gillingham, UK) supplemented with 10% fetal bovine
serum (Invitrogen, Life Technologies Ltd, Paisley, UK)
and penicillin/streptomycin (100U/ml, 100 mg/ml final
concentration; Sigma-Aldrich). Exponentially growing
cells were cultured at 371C with 95% humidified air
and 5% CO2. Cells were not passaged beyond passage 21.
Cell viability assay
Cells plated at a density of 1 103 cells/cm2 were incubated
overnight and treated for 24, 48, or 72h with five
concentrations (1–20mmol/l) of clozapine (Sigma-Aldrich)
or with 1.3% dimethyl sulfoxide (DMSO; Sigma-Aldrich)
vehicle control. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) salt assay was performed to
test cell viability (Mosmann, 1983). Data shown represent
triplicate wells from three independent experiments.
Drug treatment
Clozapine dissolved in DMSO at a final concentration of
1, 2, 5, 10, or 20 mmol/l or vehicle, as described in the Cell
viability section, was added to SH-SY5Y cells. Cells were
incubated for 24, 48, or 72 h. Drug administration was
performed in triplicate and repeated in three separate
cultures to yield nine replicates for each time point and
concentration of clozapine or vehicle.
RNA extraction
RNA was extracted using the Illustra RNAspin mini RNA
isolation kit (GE Healthcare Life Sciences, Little Chalfont,
Buckinghamshire, UK) and quantified using a Nanodrop
ND-1000 (Labtech International Ltd, Uckfield, UK). The
RNA purification kit includes an on-column DNase I digest
step to avoid contamination with genomic DNA and to
improve the purity of the RNA (GE Healthcare Life
Sciences). All samples had a 260 : 280 nm ratio of more than
1.6. RNA was then stored at – 801C until required for
reverse transcription (RT) into cDNA.
Reverse transcription
RNA was diluted with PCR-grade water (Sigma-Aldrich) to
obtain an equal amount of substrate for RT from each RNA
sample. Five hundred nanograms of Oligo(dT)15 Primer
(Promega UK Ltd, Southampton, UK) was added to all
RNA samples diluted to the same concentration in 11ml
and incubated at 701C for 10min. For RT to cDNA, master
mix containing 4ml 5 first-strand buffer, 10mmol/l
dithiothreitol, 200mmol/l mixed dNTPs, and 200U Super-
script III reverse transcriptase (Invitrogen) yielding a final
volume of 20ml with RNA was prepared. The reaction was
heated to 421C for 90min. To control for unwanted
amplification of contaminating genomic DNA, no-RT
samples were run that had followed the same RT procedure
without the addition of the RT enzyme. Samples were
diluted to yield a standardized concentration of cDNA on
the basis of RNA quantification of 50ng/ml, and then frozen
at – 201C until required for gene expression analysis.
RT-qPCR panel plate to screen for GPCR gene
expression
Quantitative PCR (qPCR) to assess changes in the
expression of 84 GPCR genes with the Human GPCR
RealTime ready 384-well panel plate (Roche, Burgess Hill,
UK) was performed using a 480 LightCycler (Roche). The
copy number of each GPCR gene was measured in
quadruplicate from nine pooled replicates of cDNA
samples extracted from cells following treatment with
5mmol/l clozapine for 24 h. cDNA samples were pooled to
control for variation in gene expression across the nine
replicates. A second Human GPCR RealTime ready 384-
well panel plate was used with nine pooled cDNA samples
from cells treated with DMSO for 24 h to express changes
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in GPCR gene copy number following antipsychotic drug
treatment relative to vehicle. Each well contained 5ml
(5 ng) of pooled cDNA along with 5ml of 2 LightCycler
480 probes master mix (Roche). The amplification protocol
was a one-cycle denaturing step at 951C for 10min,
followed by 45 cycles of 951C for 10 s and 601C for 30 s,
with a measurement of hydrolysis probe fluorescence using
standard FAM wavelength filter settings, and 721C for 1 s,
with a last cycle at 721C for 10min.
Crossing threshold quantification cycle (Cq) values were
obtained for all 84 GPCR genes and seven reference genes
on the GPCR panel plate. The quadruplicate average Cq of
each GPCR gene measured in cDNA from cells following
treatment with 5mmol/l clozapine for 24h was then
expressed relative to each of the seven reference genes.
These seven relative values for each GPCR gene were
averaged to yield an overall Cq for each gene. The same was
repeated for Cq values obtained from the second GPCR
panel plate with DMSO-treated cDNA. The mean GPCR
Cq values derived from the DMSO plate were subtracted
from those of the 5mmol/l clozapine plate to yield changes
in gene copy number attributable to drug treatment. From
the GPCR panel screen of 84 genes in pooled cDNA
samples, nine candidate GPCR genes showing greater than
two-fold change in expression or downregulated by 5mmol/l
clozapine treatment compared with DMSO were identified
(Fig. 2). qPCR assays for these genes, galanin receptor 2
gene (GALR2), serotonin receptor 2A (HTR2A), endo-
thelial differentiation receptor 4 (EDG4), somatostatin
receptor 3 (SSTR3), HTR7, P2Y purinoceptor 1 (P2YR1),
dopamine receptor D1 (DRD1), HTR1A, and type-1
angiotensin II receptor-associated protein (AGTRAP), were
designed to confirm the effect on the expression of five
doses of clozapine (1–20mmol/l) at all three exposure times
(24, 48, and 72h) using cDNA replicates (i.e. not pooled).
In addition, qPCR assays were designed for seven CME-
related genes including adaptor-related protein complex 2,
a2 subunit (AP2A2), adaptor-related protein complex 2, b1
subunit (AP2B1), AP180, CLINT1, disabled homolog 1 and
2 (DAB1, DAB2), Huntingtin interacting protein 1 (HIP1),
intersectin 2 (ITSN2), and phosphatidylinositol-binding
clathrin assembly lymphoid myeloid protein (PICALM).
RT-qPCR GPCR, CME, and reference gene expression
assays
Assays were designed using the Roche real-time ready con-
figurator (https://www.roche-applied-science.com/sis/realtimeready/
index.jsp) on the basis of those provided on the Roche
GPCR panel to obtain the position of the amplicon on the
gene of interest. ProbeFinder software in the Roche universal
Table 1 qPCR primers and probes
Genea Ensemble ID Sequence
50 primer position
on gene (bp)
Intron
spanning
UPL probe or
SYBR-Greenb
AGTRAP_F ENST00000376637 50-TATGCCTGGGCCAACTTCAC 162 Y 162
AGTRAP_R 50-GCAAGCCACCCAGAAACATG 273
AP180_F ENST00000521485 50-AAGGTGACATTCCTGACCTC 1178 Y 3
AP180_R 50-TAGATGCTGTTCAAGCGTCTC 1242
AP2B1_F ENST00000262325 50-GATCTCATAGCAGATTCAAATCC 688 Y 77
AP2B1_R 50-ATTTCAGATAATGCCGCTACG 749
AP2A2_F ENST00000329626 50-GTGGTGCACCTGCTCAATG 755 Y 5
AP2A2_R 50-CTTCTGGGTTCTTCTGTGC 842
CLINT1_F ENST00000296951 50-AGCAGCAAGTCATCTGGTG 1145 Y 20
CLINT1_R 50-ATGCAGCAGCTGAGCCAAAG 1256
GALR2_F ENST00000329003 50-CTACGCCAACTCCTGCGTCAAC 923 N 54
GALR2_R 50-CAGATCGTGCGGAAGCCTTTG 1001
HIP1_F ENST00000336926 50-TGCAGGACACTCAGCTCAAAC 1820 Y 6
HIP1_F 50-TTCGTTGGTCTTTGGCAAG 1889
HTR1A_F ENST00000323865 50-AGTGAAGACGCTGGGCATCA 1029 N SG
HTR1A_R 50-GCAGAAGGGCAGAACAAGAG 1113
HTR7A_F ENST00000336152 50-CAGCAGTAAGCACACCAACAG 1915 N SG
HTR7A_R 50-GGACATATGCAAAGCACCAG 1984
ITSN2_F ENST00000355123 50-TGACCTTCAGCTCGTCGTC 4122 Y 53
ITSN2_R 50-CTCCCCTTCAGTGAGAAAGC 4191
LPAR2_F ENST00000407877 50-CTGGTCAAGACTGTTGTCATCA 854 Y 120
LPAR2_R 50-CCAGGAGCAGTACCACCTG 929
P2RY1_F ENST00000305097 50-AGCGGCATCTCCGTGTACA 250 N 51
P2RY1_R 50-TGAAGTAGTAGAAGATCAGG 337
PGK1_F – – – – Roche PGK1 gene assay
PGK1_R – – –
PICALM_F ENST00000341783 50-TCTCAGGTAGCAAGTACATGG 1520 Y 5
PICALM_R 50-CAACATTAAGGCCAGCTGAAG 1748
RPLP0_F ENST00000228306 50-CGACAATGGCAGCATCTAC 816 Y 6
RPLP0_R 50-GGTAGCCAATCTGCAGAC 931
aAGTRAP, type-1 angiotensin II receptor-associated protein; AP180, clathrin coat assembly protein 180, also known as SNAP91; AP2A2, adaptor-related protein
complex 2, a2 subunit; AP2B1, adaptor-related protein complex 2, b1 subunit; CLINT1, clathrin interactor 1; F, forward primer; GALR2, galanin receptor 2;
HIP1, Huntingtin interacting protein 1; HTR1A, serotonin receptor 1A; HTR7, serotonin receptor 7; ITSN2, intersectin 2; LPAR2, lysophosphatidic acid receptor 2; N, no;
P2YR1, P2Y purinoceptor 1; PGK1, phosphoglycerate kinase 1; PICALM, phosphatidylinositol-binding clathrin assembly lymphoid myeloid protein; R, reverse primer;
RPLP0, acidic ribosomal protein P0; Y, yes.
bUPL, Roche Universal Library Hydrolysis Probe Number; SG, SYBR-Green.
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probe library (UPL) assay design center (https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp) was used to identify a
suitable predesigned UPL hydrolysis probe (Roche) for the
amplicon sequence (Table 1). Three reference genes assays
were tested for stability of expression following DMSO and
clozapine treatment. These comprised a predesigned assay
for phosphoglycerate kinase 1 (PGK1) (Roche) and two
assays designed in-house for hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) and 60S acidic ribosomal
protein P0 (RPLP0). Assays for PGK1 and RPLP0 were
selected for analysis (data not shown). Where possible,
intron-spanning gene-specific primers were designed
(Table 1) and screened in silico for specificity using the
UCSC genome browser BLAT (http://genome.ucsc.edu/cgi-bin/
hgBlat?command=start).
PCR primers were optimized in the absence of UPL
hydrolysis probes for each of the nine GPCR genes.
Where assays failed when the hydrolysis probe was added,
the DNA intercalating fluorescent dye SYBR-Green was
used instead. However, three GPCR gene assays, DRD1,
HTR2A, and SSTR3, and two CME gene assays, DAB1
and DAB2, failed despite various optimization steps.
qPCR was subsequently performed as follows: 2 ml of
cDNA (50 ng) was added to a 10 ml reaction mixture
containing SYBR-Green (Roche) diluted 1/10 000 where
appropriate, 200 mmol/l dNTPs, 1 concentrated buffer
mix containing NH4 (Bioline Ltd, London, UK), 3.2 or
6.2mmol/l MgCl2, 400 nmol/l of each primer, and 0.5U of
Taq DNA polymerase. Cycling conditions were one
denaturing cycle of 10min at 951C, followed by 45 cycles
of denaturation (951C for 30 s), annealing (601C for 30 s),
and extension (721C for 10 s), with a final 10-min
extension at 721C. For SYBR-Green qPCR, dissociation
curve analysis was carried out at 951C for 5 s, 651C for
1min, and then 971C at a ramp rate of 0.111C/s with five
fluorescence acquisitions per 1C. PCR products were
visualized by gel electrophoresis in 3.0% (w/v) agarose
and then purified by adding an equal volume of
microclean (Microzone Ltd, Haywards Heath, UK),
centrifuging for 10min at 13 000g, and resuspending in
20 ml water. The mass of the PCR product was quantified
using a Nanodrop ND-1000 spectrophotometer. Using
the amplicon size and a copy number calculator (http://
www.uri.edu/research/gsc/resources/cndna.html), the PCR pro-
ducts were quantified.
Efficiencies and standard curves
Following optimization of qPCR expression assays for six
GPCR, seven CME-related, and two reference genes, the
efficiency of each assay was tested using five serial
dilutions of purified PCR products and reference cDNA
as amplification templates. The logarithm of the initial
template copy number was plotted against the Cq value.
The efficiency was calculated as follows: E=10 –
(1/slope), with a value of two indicating a doubling of
copy number per cycle and perfect efficiency. Efficiency
values were accepted at 2±5%. qPCR was performed in a
384-well plate format in quadruplicate for 1 ml cDNA,
equivalent to 50 ng RNA, from each time point and
treatment condition, in a 4ml reaction mixture as described
above, containing 100nmol/l Roche UPL hydrolysis probe
where appropriate using an Epmotion 5075 (Eppendorf UK
Ltd, Stevenage, UK) robot and a LightCycler 480 (Roche).
A calibrator sample of cDNA was used on all 384-well
plates to control for variance between plates, along with an
H2O-negative control.
qPCR gene expression statistical analysis
Raw data analysis
Quadruplicate Cq values for each cDNA sample were
averaged. Where the SEM was greater than 1%, either
one of the replicate values was deleted to yield an SEM
less than 1% or the entire mean value was deleted.
Changes in gene transcription were evaluated using the
2DC
0
q method (Livak and Schmittgen, 2001). The mean
Cq values of each target gene were expressed relative to
the mean Cq values of the two reference genes (2
DC0q).
The mean Cq values of the calibrator were then
subtracted from the relative mean Cq values on each
plate. The 2DDC
0
q method based on normalization with
the mean of the reference genes was applied for the
GPCR panel plate to determine differences in concen-
trations between samples. The 2DC
0
q of the different
Fig. 1
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clozapine drug treatment samples were compared directly
with that of the DMSO vehicle sample to yield 2DDC
0
q .
Removal of extreme outliers
Data for 2DC
0
q derived from gene expression assays were
initially examined by boxplot analysis to identify outliers.
cDNA with 2DC
0
q values between 1.5 and 3 box lengths
(box length being the interquartile range) from the upper
or the lower edge of the box were classified as an outlying
value (SPSS version 17.0; IBM UK Ltd, Portsmouth, UK),
but were included in the analysis. Values for cDNA more
than three box lengths from the upper or the lower edge
of the box, or extreme outliers, three or more SDs from
the mean, were excluded from analysis. Results are given
as group means with respect to time point and DMSO or
clozapine treatment minus outliers along with SEM
determined from the number (n) of replicates. Parametric
statistical evaluations were performed using one-way
analysis of variance (ANOVA) to compare the means
between three or more treatment groups and Student’s
t-test for the comparison of two treatment groups. If
homogeneity of variance (Levene’s test for equality of
variances) was significantly different between subject
groups, then a nonparametric analysis was carried out
(Kruskal–Wallis for three or more groups; Mann–Whitney
U-test for two groups) when appropriate (SPSS version
17.0). A cut-off significance value of P less than 0.05 was
used.
Microarray statistical analysis of clozapine treatment
in mice
Mice were administered 12mg/kg/day clozapine (Novartis
Pharma AG, Basel, Switzerland) in drinking water at a
concentration equivalent to the highest human clinical
dosage in a 12-week study (10 clozapine treated and 10
untreated controls) (Rizig et al., 2012). At the end of
treatment, mice brains were dissected and total RNA was
extracted from the right and the left cerebral hemispheres.
mRNA was prepared and hybridized to MOE430A
Affymetrix arrays (Affymetrix UK Ltd, High Wycombe,
UK) before being scanned using the Affymetrix GeneChip
Scanner 3000 (Rizig et al., 2012). All Affymetrix arrays
Fig. 2
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fulfilled the recommended quality control criteria. Con-
sistency between the intensity of replicates was investi-
gated with box plots and histograms. Raw and normalized
data are available at: http://www.ncbi.nlm.nih.gov/projects/geo/
query/acc.cgi?acc=GSE6512. Normalization of arrays was
performed using GC-RMA (Gentleman et al., 2004) and
probe values that passed detection-significance thresholds
for CME-associated and GPCR genes were extracted. The
log 2 output values from GC-RMA were antilogged to allow
the calculation of fold changes of significant genes from the
mean intensity of expression of grouped samples. Multi-
variate analysis of variance (MANOVA) test on several
probe sets or a Student’s t-test for a single probe was used
on log10-transformed data to identify significant changes in
mRNA expression (SPSS version 17.0). A cut-off signifi-
cance value of P less than 0.05 was used.
Results
Cell viability assay
Cell viability between 94 and 100% was unchanged after
incubation with 1 or 2 mmol/l clozapine for 24 and 48 h,
compared with vehicle. However, MTT-formazan forma-
tion decreased with increasing concentrations of cloza-
pine (5–20 mmol/l) at 24- and 48-h incubation times,
indicating decreasing SH-SY5Y cell viability. Interestingly,
the rate of cell growth and survival increased by 29% with
both 1 and 2 mmol/l clozapine, and by 15% with 5 mmol/l
clozapine following a 72-h incubation compared with
vehicle. There was no difference in cell viability between
vehicle and 10 mmol/l clozapine after 72 h, suggesting that
chronic exposure to lower concentrations of clozapine
exerts a protective effect and actually stimulates cell
proliferation. However, incubation of cells with 20 mmol/l
clozapine for 24, 48, and 72 h resulted in a mean cell
death of 58, 46, and 42%, respectively, relative to vehicle
(Fig. 1).
In-vitro CME gene expression
We show that clozapine alters mRNA expression for
markers of the CME system in SH-SY5Y cells (Table 2)
including AP2B1 (Kruskal–Wallis, 48h: w2=16.731, d.f.=5,
P=0.005; 72 h: w2=17.385, d.f.=5, P=0.004), AP180
(Kruskal–Wallis, 48h: w2=18.230, d.f.=5, P=0.003; 72 h:
w2=32.105, d.f.=5, P=0.0006), HIP1 (Kruskal–Wallis,
48 h: w2=15.895, d.f.=5, P=0.007; 72 h: w2=11.543,
d.f.=5, P=0.042), ITSN2 (Kruskal–Wallis, 48h:
w2=15.264, P=0.009; 72h: w2=15.680, P=0.008), and
PICALM (Kruskal–Wallis, 48h: w2=15.005, d.f.=5,
P=0.010). The change in expression of PICALM compar-
ing the five clozapine treatments with vehicle at 72 h
approached, but did not reach, significance (Kruskal–Wallis,
w2=10.965, d.f.=5, P=0.052). There were no statistically
significant changes in the expression of these CME-
associated genes following the more acute 24-h treatment
(AP2B1: Kruskal–Wallis, w2=6.333, d.f.=5, P=0.275;
AP180: one-way ANOVA, F=1.141, P=0.360; HIP1:
one-way ANOVA, F=0.585, P=0.712; ITSN2: one-way
ANOVA, F=1.745, P=0.149; PICALM: one-way ANOVA,
F=0.451, P=0.809). There were no significant differ-
ences between the treatment group means for AP2A2 and
CLINT1 genes at any time point (one-way ANOVA,
P>0.05).
GPCR gene expression screening
Because of the large number of molecular targets that are
implicated in the action of clozapine, we screened the
expression of 84 GPCR genes in cDNA from cells
incubated with 5mmol/l clozapine for 24 h. GPCR gene
expression was presented relative to the average expression
of six reference genes (ACTB, B2M, GAPDH, HPRT1,
RPL13A, and YWHAZ) and fold change was compared from
clozapine-treated cells with that of DMSO vehicle-treated
cells. Expression data for one reference gene, 18S, were
significantly altered by clozapine treatment and were thus
excluded from analysis. Of the 84 GPCR genes screened,
there were consistent data for both clozapine-treated and
DMSO-treated cDNA for 29 genes only (Fig. 2). Among
the GPCR genes with an increase in fold change of two or
greater, clozapine treatment increased the expression of
three 5-HT receptor genes (HTR1A, HTR2A, and HTR7)
and DRD1. These four GPCRs are among those reported
to be pharmacological targets of clozapine (Meltzer and
Massey, 2011). The highest increases in gene expression
following clozapine treatment were observed for the 5-
HT2A gene (HTR2A), with an 11.6-fold change, and the
GALR2 gene, with an 11.1-fold change relative to the
control. Gene expression was downregulated for arrestin
b-2 (ARRB2) and AGTRAP following clozapine treatment,
with a – 0.39 and – 0.92 decrease in fold change relative to
the controls, respectively. It is also of interest that the
expression of three endothelial differentiation GPCR genes
(EDG), EDG4 (also known as lysophosphatidic acid
receptor 2, LPAR2), EDG5, and EDG1 (also known as
sphingosine-1-phosphate receptors S1PR 2 and 1, respec-
tively) was upregulated between one and seven fold
following clozapine treatment (Fig. 2).
GPCR gene expression
Given that the GPCR panel plate offers a rapid screening
method to identify the change in gene expression from
pooled cDNA, it was important to determine the changes
in unpooled cDNA from cells treated with the range of
concentrations over the time course. The genes with the
highest fold change in expression were thus followed up
with individual qPCR gene expression assays to measure
the effect of drug treatment more accurately. We selected
the eight genes with the highest fold increases in
expression, that is, HTR2A–HTR1A (Fig. 2), and AGTRAP
as this showed the highest fold decrease in expression
relative to the control (Table 2). We show that EDG4
mRNA expression is altered by 48-h clozapine treatment
in human neuroblastoma cells (EDG4, one-way ANOVA,
F=2.921, P=0.022). Bonferroni adjustment of EDG4
expression from all five clozapine treatment groups
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compared with the control was not significant (one-way
ANOVA Bonferroni post-hoc test, 1 mmol/l: P=1.000;
2 mmol/l: P=1.000; 5 mmol/l: P=1.000; 10 mmol/l:
P=0.544; 20 mmol/l: P=0.086), the significant differ-
ence between groups being driven by the increase in
EDG4 expression following 20 mmol/l clozapine treatment
(Table 2). There was a trend toward changed EDG4
expression after 72 h of treatment (one-way ANOVA,
24 h: F=0.160, P=0.976; 72 h: F=2.195, P=0.071).
The mean comparisons of treatment groups are not
significantly different for AGTRAP, P2YR1, GALR2,
HTR1A, and HTR7 genes at any time point (P>0.05).
Clozapine expression profiles in the mouse brain
The full Affymetrix array list of gene mRNA expression in
the mouse brain following a 12-week chronic treat-
ment with clozapine or vehicle can be downloaded from
http://www.ucl.ac.uk/˜rejuhxg/ClozHalStudy/. Clozapine signifi-
cantly altered the expression of 1330 genes relative to
control. Clozapine altered the expression of nine GPCR and
CME genes in the mouse brain with increases in AP2A2 by
3.8-fold (MANOVA, F=46.527, d.f.=4, N=76, P=
6.16 108), AP2B1 by 2.7-fold (MANOVA, F=98.520,
d.f.=2, N=40, P=4.46 108), AP180 by 641.0-fold
(Mann–Whitney U-test, Z= –3.782, N=20, P=1.08
Table 2 SH-SY5Y neuroblastoma gene expression following treatment with clozapine (1–20 lmol/l) for 24, 48, and 72h
Clozapine treatmentb
Treatment time Genea DMSO 1mmol/l 2mmol/l 5mmol/l 10 mmol/l 20 mmol/l
24 h AP2A2 0.59±0.06 (7) 0.89±0.22 (8) 0.93±0.19 (7) 1.28±0.32 (9)*,c 0.66±0.06 (7) 0.53±0.16 (5)
CLINT1 1.88±0.32 (9) 1.36±0.17 (8) 2±0.6 (9) 1.84±0.43 (8) 1.51±0.23 (8) 0.78±0.27 (6)
AP2B1 1.13±0.35 (4) 2.5±1.18 (5) 3.97±2.45 (3) 1.08±0.34 (4) 1.12±0.32 (4) 3.19±0.7 (4)
AP180 2.08±0.78 (8) 1.21±0.3 (7) 1.18±0.33 (7) 1.38±0.34 (6) 1.37±0.41 (5) 2.69±0.35 (4)
HIP1 1.75±0.63 (8) 2.4±1.22 (8) 1.92±0.81 (5) 1.33±0.58 (6) 0.69±0.21 (5) 0.84±0.15 (4)
PICALM 1.57±0.56 (8) 1.08±0.33 (7) 2.35±1.23 (8) 1.23±0.35 (6) 1.27±0.37 (6) 1.76±0.38 (4)
ITSN2 0.52±0.16 (8) 0.32±0.09 (7) 0.58±0.25 (8) 0.35±0.11 (7) 0.39±0.15 (7) 0.97±0.19 (6)
AGTRAP 1.69±0.49 (9) 2.02±0.52 (7) 1.45±0.39 (9) 1.82±0.43 (7) 1.49±0.34 (8) 1.9±0.41 (7)
P2YR1 10.4±7.4 (4) 33.55±11.12 (4) 12.02±6.48 (7) 25.42±15.71 (6) 33.4±21.26 (8) 28.23±18.17 (5)
EDG4 1.38±0.41 (8) 1.48±0.45 (8) 1.78±0.53 (9) 1.7±0.45 (9) 1.58±0.35 (9) 1.82±0.35 (8)
GALR2 2.01±0.94 (7) 9.73±5.68 (6) 7.85±3.77 (7) 15.45±8.12 (8) 1.28±0.53 (5) 4.53±1.96 (5)
HTR1A 0.48±0.17 (5) 3.9±1.85 (8) 2.88±1.58 (8) 5.24±2.97 (8) 9.29±6.06 (7) 1.75±0.72 (7)
HTR7 5.22±2.57 (6) 17.03±8.02 (7) 9.86±5.46 (7) 21.7±11.71 (6) 27.39±16.82 (6) 21.53±12.6 (6)
48 h AP2A2 0.76±0.15 (9) 1.06±0.12 (9) 0.94±0.15 (8) 0.75±0.09 (7) 1.26±0.43 (9) 1.49±0.4 (9)
CLINT1 0.72±0.14 (8) 0.9±0.07 (9) 0.89±0.16 (8) 0.86±0.13 (8) 0.95±0.14 (8) 1.54±0.38 (8)
AP2B1 0.15±0.03 (9) 0.2±0.04 (9) 0.28±0.09 (9) 0.17±0.04 (8) 0.15±0.04 (7) 1.17±0.24 (9)
AP180 0.04±0.01 (9) 0.04±0.01 (8) 0.08±0.02 (9) 0.05±0.08 (8) 0.04±0.01 (7) 1.13±0.31 (8)
HIP1 0.1±0.02 (9) 0.11±0.02 (9) 0.15±0.04 (9) 0.08±0.02 (8) 0.07±0.02 (7) 1.39±0.37 (9)
PICALM 0.12±0.03 (9) 0.12±0.03 (9) 0.17±0.05 (9) 0.11±0.03 (8) 0.09±0.02 (7) 0.94±0.21 (9)
ITSN2 0.03±0.01 (8) 0.05±0.02 (9) 0.04±0.02 (8) 0.02±0.01 (7) 0.21±0.14 (8) 0.25±0.03 (7)
AGTRAP 0.76±0.13 (9) 0.95±0.17 (9) 1.02±0.2 (9) 0.77±0.14 (9) 1.13±0.18 (9) 0.83±0.13 (9)
P2YR1 3.89±2.24 (5) 2.32±1.32 (6) 3.42±1.17 (4) 6.71±3.68 (6) 4.1±2.09 (4) 2.13±1.02 (4)
EDG4 0.78±0.08 (9) 0.86±0.08 (9) 0.93±0.08 (9) 0.77±0.07 (9) 1.06±0.11 (9) 1.15±0.12 (9)*,i
GALR2 1.51±0.5 (9) 1.46±0.45 (7) 1.21±0.45 (8) 2.36±1.16 (8) 0.91±0.38 (7) 1.72±0.81 (8)
HTR1A 0.67±0.22 (7) 0.51±0.1 (7) 1.34±0.48 (8) 4.42±2.7 (8) 0.49±0.12 (6) 2.31±1.14 (7)
HTR7 3.04±1.78 (5) 1.56±0.48 (5) 1.19±0.37 (7) 4.87±2.86 (8) 1.54±0.94 (4) 4.04±2.57 (4)
72 h AP2A2 137.07±18.76 (9) 131.58±16.9 (9) 105.89±17.11 (9) 118.2±23.12 (9) 118.8±18.53 (9) 148.81±26.62 (7)
CLINT1 0.06±0.01 (9) 0.06±0.01 (9) 0.06±0.01 (9) 0.07±0.01 (9)*,d 0.06±0.01 (9) 0.07±0.01 (8)
AP2B1 6.62±0.61 (9) 6.21±0.87 (9) 6.2±0.6 (9) 7.69±0.81 (9) 6.23±0.67 (8) 25.77±6.94 (7)
AP180 1.74±0.06 (7) 1.77±0.16 (9) 1.78±0.15 (9) 2.81±0.22 (9)*,e 2.28±0.09 (9)***,g 32.32±12.57 (7)
HIP1 6.63±0.83 (9) 7.64±1.24 (9) 6.74±0.89 (9) 8.6±1.02 (9) 7.9±1.16 (9) 21.18±5.46 (7)
PICALM 12.6±1.02 (9) 11.91±1.38 (9) 11.99±0.78 (9) 16.2±1.2 (9)*,f 13.93±0.93 (9) 23.11±5.5 (8)
ITSN2 0.26±0.03 (8) 0.32±0.07 (9) 0.26±0.05 (8) 0.32±0.05 (8) 0.41±0.11 (9) 7.76±3.73 (9)
AGTRAP 1.14±0.1 (9) 1.18±0.08 (9) 1.08±0.07 (9) 1.24±0.1 (9) 1.27±0.09 (9) 1.26±0.14 (8)
P2YR1 0.88±0.39 (8) 0.9±0.32 (6) 0.72±0.22 (6) 2.21±0.87 (7) 0.76±0.27 (6) 2.22±0.73 (4)
EDG4 1.28±0.08 (9) 1.43±0.12 (9) 1.34±0.04 (9) 1.62±0.14 (9) 1.69±0.06 (9)**,h 1.48±0.19 (7)
GALR2 1.92±0.54 (9) 2.44±0.72 (8) 1.49±0.2 (7) 3.88±1.32 (9) 1.34±0.51 (9) 2.36±0.84 (7)
HTR1A 0.71±0.23 (6) 1.1±0.44 (7) 0.92±0.29 (8) 2.43±0.73 (8) 0.93±0.23 (8) 1.71±0.56 (7)
HTR7 1.17±0.33 (7) 1.89±0.48 (5) 2.52±1.04 (8) 1.64±0.52 (7) 0.86±0.33 (6) 1.78±1.14 (6)
Data are mean 2DC
0
q±SEM (n). Bold indicates that the fold change in gene expression following clozapine treatment is significantly different relative to vehicle.
aAGTRAP, type-1 angiotensin II receptor-associated protein; AP180, adaptor protein 180; AP2A2, adaptor-related protein complex 2, a2 subunit; AP2B1, adaptor-
related protein complex 2, b1 subunit; CLINT1, clathrin interactor 1; DMSO, dimethyl sulfoxide; EDG4, encoding LPAR2, lysophosphatidic acid receptor 2; GALR2,
galanin receptor 2; HIP1, Huntingtin interacting protein 1; HTR1A, serotonin receptor 1A; HTR7, serotonin receptor 7; ITSN2, intersectin 2; P2RY1, P2Ypurinoceptor 1;
PGK1, phosphoglycerate kinase 1; PICALM, phosphatidylinositol-binding clathrin assembly lymphoid myeloid protein; RPLP0, acidic ribosomal protein P0.
bGene expression relative to two reference genes: PGK1 and RPLP0.
Significant Students t-test or Mann–Whitney U-test results are shown for comparisons between treatment groups:
DMSO vs. 5 mmol/l CLZ: cAP2A2_24 h, Z= –2.276, P=0.023; dCLINT1_72 h, t=0.634, d.f.=16, P=0.033; eAP180_72 h, Z= –3.228, P=0.01; fPICALM_72 h,
t= –2.291, d.f.=16, P=0.036.
DMSO vs. 10 mmol/l CLZ: gAP180_72 h, t= –4.524, d.f.=14, P=0.0005; hEDG4_72 h, t= –3.912, d.f.=16, P=0.001.
DMSO vs. 20 mmol/l CLZ: iEDG4_48 h, t= –2.586, d.f.=16, P=0.02.
*P<0.05; **P<0.01; ***P<0.001.
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10–5), CLINT1 by 4.5-fold (Mann–Whitney U-test,
Z= –3.558, N=18, P=4.57 10–5), HTR1A by 16.7-fold
(Mann–Whitney U-test, Z= –3.782, N=20, P=1.08
10–5), and PICALM by 2.6-fold (Mann–Whitney U-test,
Z= –3.782, N=20, P=1.08 10–5), whereas the expres-
sion of three genes was significantly decreased including
ARRB2 by 7.6-fold (MANOVA, F=422.140, d.f.=2,
N=38, P=6.53 1014), HIP1 by 3.2-fold (Student’s
t-test, t=12.538, d.f.=18, N=20, P=2.48 1010), and
ITSN2 by 19.9-fold (MANOVA, F=317.347, d.f.=3,
N=60, P=1.85 1014) (Fig. 3 shows the logged mRNA
fold change).
Discussion
Here, we show that clozapine upregulates mRNA levels of
GPCRs and genes involved in CME function in vitro and
in vivo. The therapeutic efficacy of most typical antipsycho-
tics is related to dopamine D2/D3 receptor blockade,
whereas serotonergic actions, notably 5-HT2A receptor
antagonism, are thought to explain the differential effects
of atypical antipsychotics (Meltzer and Massey, 2011). Our
study shows a marked increase in HTR2A mRNA after 24h
of clozapine treatment in vitro. Clozapine downregulates 5-
HT2A cell surface expression and increases receptor
internalization through CME both acutely in vitro and
chronically in vivo (Berry et al., 1996; Willins et al., 1998; Will-
ins et al., 1999). Thus, the increase in HTR2A/7 expression
we observe following acute clozapine treatment may reflect
a homeostatic upregulation of postsynaptic 5-HT2A/7
receptors. In contrast, acute clozapine exposure was shown
to downregulate HTR2A expression in hippocampal cells
(Heiser et al., 2004). Recently, chronic clozapine treatment
was shown to reduce histone acetylation of the HTR2A
promoter, corresponding with decreases in transcriptional
activity, mRNA expression, and 5-HT2A density through
upregulation of histone deacetylase 2 in the frontal cortex of
mice and schizophrenia patients (Kurita et al., 2012; Moreno
et al., 2012). In untreated schizophrenia patients, frontal
cortical 5-HT2A receptors are upregulated relative to control
(Gonzalez-Maeso et al., 2008) whereas in individuals with
schizophrenia with a history of antipsychotic medication,
there is reduced frontal cortical 5-HT2A protein and mRNA
(Burnet et al., 1996), and hippocampal HTR6/7mRNA (East
et al., 2002). Both 5-HT1A mRNA levels and binding density
were also increased in the prefrontal cortex of treated
schizophrenia patients (Burnet et al., 1997). Our observed
increase in HTR2A/7 following acute clozapine exposure
may result in an increased need for presynaptic inhibition by
5-HT1A receptors, explaining the upregulation of HTR1A
in vitro and in vivo. This finding is of particular interest,
given the importance of the presynaptic serotonergic system
in the action of clozapine, requiring intact 5-HT releasing
neurons with functional 5-HT1A autoreceptors, indepen-
dent of functional postsynaptic markers such as 5-HT2A
(Yadav et al., 2011). It is essential to further characterize the
short-term and long-term clinical effects of clozapine on the
serotonergic system.
In this study, the clozapine-induced increase in 5-HT
receptor expression at 24 h is accompanied by increases in
GALR2 and EDG4/5/1, which is sustained for EDG4 at 48
and 72 h in vitro. Serotonin receptors form hetero-
oligomers with the EDG1 receptor (Salim et al., 2002)
and are coexpressed with galanin receptors, which mod-
ulate serotonergic transmission (Borroto-Escuela et al.,
2010). Interestingly, galanin receptors are implicated in
susceptibility to depression (Kuteeva et al., 2010). Similarly,
both DRD1 and SSTR3 (somatostatin 3 receptor) expres-
sions were upregulated by clozapine in vitro. Chronic
clozapine treatment in vivo is shown to increase preproso-
matostatin mRNA in the nucleus accumbens. Dopamine
regulates central somatostatinergic neurons, which play an
important role in clozapine’s superior profile in the control
of motor behavior (Salin et al., 1990).
In schizophrenia, changes in dopamine receptor traffick-
ing to lysosomes because of increased receptor agonism
Fig. 3
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Log10 transformation of fold change in clathrin-coated vesicles and
G protein-coupled receptor gene expression in mouse brain following
treatment with 12mg/kg/day clozapine for 12 weeks: data from a
microarray study. AP180, clathrin coat assembly protein 180, also
known as synaptosomal-associated protein, SNAP91; AP2A2,
adaptor-related protein complex 2, a2 subunit; AP2B1, adaptor-related
protein complex 2, b 1 subunit; ARRB2, arrestin b-2; CLINT1, clathrin
interactor 1; HIP1, Huntingtin interacting protein 1; HTR1A, serotonin
receptor 1A; ITSN2, intersectin 2; PICALM, phosphatidylinositol-
binding clathrin assembly lymphoid myeloid protein. Data are from
10 microarray replicates. The mean fold change in gene expression is
defined as gene expression in 12mg/kg/day 12-week clozapine-treated
mice relative to DMSO vehicle control mice.
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lead to more receptors being retained on the cell surface
(Iizuka et al., 2007). GPCR agonism (Traub, 2009), and
less commonly antagonism (Willins et al., 1998; Willins
et al., 1999; Heusler et al., 2008), results in receptor
internalization from the plasma membrane to the CME
pathway. Thus, post-endocytic mechanisms regulating
surface expression and lysosomal degradation of GPCRs
may be dysfunctional in subtypes of schizophrenia
(Marley and von Zastrow, 2010). Distinct populations of
CCVs sort GPCR cargo at the membrane involving
differential kinase-dependent processes. P2Y1 receptor
internalization is G protein-coupled receptor kinase
(GRK) and arrestin independent but requires protein
kinase C, whereas P2Y12 and b2 adrenergic receptors
(ADRB2) are internalized by a separate mechanism
involving GRKs and arrestin (Mundell et al., 2006).
Therefore, our data showing increased P2YR1 and ADRB2
expression suggest that clozapine affects both kinase-
dependent CCV internalization processes.
ARRB2, a functional cofactor of b-adrenergic receptor
kinase that phosphorylates the agonist-occupied receptor,
replaces receptor-associated G-proteins and prevents
reassociation. Thus, ARRB2 plays a major role in
determining homologous agonist-mediated desensitiza-
tion of GPCRs and inhibits cellular responses (Gurevich
et al., 2008). There is recent evidence that agonism of
some GPCRs does not result in the activation of signaling
pathways typical of G-proteins, but does activate MAP
kinases through b-arrestins (Rajagopal et al., 2010).
Interestingly, both the GPCR panel plate screen and
microarray data show a downregulation of ARRB2. This
decrease occurs despite a concurrent upregulation of
ADRB1/2 in vitro, suggesting that clozapine treatment
results in reduced inhibitory control of synaptic transmis-
sion despite increased adrenergic receptor agonism and
gene expression. Arrestins regulate GPCR endocytosis
through a clathrin-dependent and dynamin-dependent
pathway (Wolfe and Trejo, 2007). It is therefore likely
that clozapine’s regulation of ARRB2 affects cell surface
expression of multiple GPCRs and their trafficking
through different clathrin adaptors.
We found significant increases in the gene expression of
AP2A2 after 24 h along with CLINT1 and clathrin
assembly proteins AP180 and PICALM after 72 h of
clozapine treatment in SH-SY5Y cells compared with the
control. Clozapine increased AP2B1, AP180, HIP1, ITSN2,
and PICALM gene expression in a dose-dependent
manner at both 48 and 72 h. These increases in mRNA
levels are in keeping with the maintenance of SH-SY5Y
cell proliferation and viability when treated with lower
clozapine doses (1–10 mmol/l) for 72 h. However, high
concentrations of clozapine halved cell viability, perhaps
caused by the formation of electrophilic reactive meta-
bolites (Takakusa et al., 2008). It is important to note that
although the use of undifferentiated SH-SY5Y cells avoids
possible confounding effects on gene expression asso-
ciated with the different phenotypes induced by
various differentiation agents, these cells do not express
typical markers of mature neurons (Pahlman et al., 1984;
Adem et al., 1987). Similar to the in-vitro data, clozapine-
treated mouse microarray analysis showed that AP180,
AP2A2, AP2B1, CLINT1, and PICALM CME-gene mRNA
levels were also significantly upregulated, whereas HIP1
and ITSN2 were downregulated.
Taking our in-vitro and in-vivo data together, clozapine
increases the expression of genes encoding GPCRs and
proteins that are structurally important in CME function,
but it decreases the expression of ARRB2 that regulates
receptor endocytosis. An increase in synaptic receptor
density and/or desensitization may in turn lead to more
rapid recycling of functional receptors through CCVs, or
increased degradation of dysfunctional receptors through
the lysosomal pathway, perhaps resulting in increased
gene transcription. The early increase in GPCR gene
expression is consistent with the idea that the anti-
psychotic response occurs in the initial days following
treatment (Agid et al., 2006). Thus, CME may play a
fundamental role in the mechanism of action of
clozapine, which must be elucidated at the protein and
cellular level to develop new treatments and preventive
strategies to avoid serious side effects and improve the
prognosis of schizophrenia.
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